Name: 7th International Conference on Epigenetics and Cancer Medicine
Start: 2019-10-23
End: 2019-10-24
Location: Dubai, UAE

epigenetics conference, cancer conference, cancer conference Japan, epigenetics and cancer 2019, epigenetics congress, nursing conference, cancer epigenetics, genetics conference, Tokyo, Japan

Renowned Speakers

Suraiya Rasheed

University of Southern California USA

Jenny Wang

University of New South Wales Australia

Manal H Al Khanbashi

Higher College of Technology Oman

Pedro Sanchez Rovira

Xanit International Hospital Spain

David A Ligon

Oncology Fox LLC USA

Atsushi Kaneda

Chiba University Japan

Ladan Teimoori-Toolabi

Pasteur Institute of Iran Iran

Sang Hyun Lee

Duke-NUS Medical School Singapore

Recommended Global Oncology & Cancer Webinars & Conferences

Europe & UK

Cancer Meeting Summit 2025, France Women Oncology-2025, UK CANCER2025, Netherlands Breast Cancer Summit 2025, Italy Cancer Stem Cells 2025, Netherlands

Asia Pacific & Middle East

Canada

epigenetics conference 2019

About Conference

Epigenetics and Cancer 2019 conference is mainly focused on the progress of the scientific community (may it be research, clinical trials, and nursing) against Cancer. It demonstrates the amazing science of Cancer Epigenetics and its promising aspects of treatment. Showcasing the new scientific and technical advances in comparison to the ancient theories, it manifests the connection of research and a patient.

Who Should Attend??

Epigenetics and Cancer 2019 Conference is a novel discussion to unite overall recognized scholastics in the field of Oncology, Genetics, Epigenetics, Genomics and Proteomics, Bioinformatics, Molecular Biology Researchers, Public wellbeing experts, Scientists, Academic researchers, Industry specialists, Scholars to exchange about the state of the Research and Development.

Target Audience:

Scientists
Professors
Doctors
Students
Nurses
Patient Advocates
Business delegates

Why Should Attend??

The arranging group assembles eminent speakers covering the most recent advances in the field, fusing differing qualities in each sense. We likewise incorporate talks on most recent methodologies for concentrating these biological inquiries.

The conference focuses on the wider aspect of the scientific contribution to showcase the new scientific and technical advances in comparison to the ancient theories. Your perspective and our visualization together will set a platform for the exchange of ideas towards contribution to advanced innovation.

We encourage multidisciplinary approach as well. Not only speaker presentations but also workshops, exhibition and networking opportunities are available. A Unique Opportunity for Advertisers and Sponsors at this International event.

Benefits:

All accepted abstracts will be published in the supporting journals of the conference and Conference Book Proceeding.
Each abstract will receive a DOI number provided by Crossref
Opportunity to conduct Workshop with your team members
One to One Interaction with Keynote Speakers, OCM and Eminent personalities for the future course of work.
Opportunity to chair a session.
Certification by the organizing committee.
Individual keynote Page will be created to get more visibility for your scientific research.
Huge Benefits on Group Registration and much more.

Suggestions

Have Suggesstions? Get 30% OFF on Registrations

Epigenetics and Cancer 2019 is accepting suggestions for the Conference programme.

Persons interested to attend the conference can suggest a topic/session or any speaker that they would like to see in the Conference programme. If the session is selected for the conference program by the committee members, you can stand a chance to avail 30% discount on registration.

Would you like to suggest a session/speaker? Let us know by completing the FORM.

Session Topics

Track 1: Cancer

When the body's control mechanism stops working properly and the cells remain no longer normal, they start growing abnormally and uncontrollably, hence causing Cancer. Old cells do not die and instead grow out of control, forming new, abnormal cells. These extra cells may form a mass of tissue, called a tumor. A tumor can be benign and malignant as well. Benign tumors lack the ability to metastasize whereas malignant are life-threatening and metastasize which leads to cancer.

There are different types of cancers. Despite of their characteristics to grow, divide & re-divide (instead of dying) and forming new abnormal cells, some types of cancer cells often travel to other parts of the body through blood circulation or lymph vessels (metastasis), where they begin to grow. Different types of cancer cells can behave differently.

The risk of developing many types of cancers can be reduced by changes in lifestyle by quitting smoking and eating low fat diet, etc., If cancer is identified in early stage it is easy to treat and may have better chances for living many years.

33^rd Global Experts Meeting on Cancer Science & Therapy, April 29-30, 2019 Seoul, South Korea | 3^rd Global Summit on Oncology & Cancer, May 6-7, 2019 Tokyo, Japan | 16^th Asia Pacific Oncologists Annual Meeting, May 13-14, 2019 Singapore | 17^th International Conference on Cancer Research and Therapy, February 27-28, 2019 Seoul, South Korea | 34^th Euro-Global Summit on Cancer Therapy & Radiation Oncology, July 25-27, 2019 London, UK | 26^th Cancer Genomics Congress: New Era for Cancer Prevention, January 21-22, 2019 Dubai, UAE | 17^th International Conference on Cancer Research and Therapy, February 27-28, 2019 Seoul, South Korea | 24^th Annual meet on Surgical Oncology, March 4-5, 2019 Paris, France | 32^nd Euro Congress on Cancer Science & Therapy, March 07-08, 2019 Barcelona, Spain | 15^th Global Biomarkers Summit, March 20-21, 2019 Paris, France | 4^th World Conference on Breast and Cervical Cancer, October 14-15, 2019 Helsinki, Finland | 31^st Experts Meet On Cancer Therapy, September 13-14, 2019 Singapore | 5^th International Congress on Epigenetics & Chromatin, August 22-23, 2019 Vienna, Austria | 6^th World Congress on Epigenetics and Chromosome, November 22-23, 2019 Dubai, UAE

Asian Societies

European Societies

USA Societies

Track 2: Cancer Genomics and Epigenomics

Cancer genomics is the study of the complete set of DNA sequence and differences between gene expression of tumor cells and normal host cells. It aims to understand the genetic basis of tumor cell proliferation and the evolution of the cancer genome under mutation and selection by the body environment, the immune system and therapeutic interventions. Epigenomics is the study of the total epigenetic modifications on the genetic material of a cell.

26^th Cancer Genomics Congress: New Era for Cancer Prevention, January 21-22, 2019 Dubai, UAE | 17^th International Conference on Cancer Research and Therapy, February 27-28, 2019 Seoul, South Korea | 24^th Annual meet on Surgical Oncology, March 4-5, 2019 Paris, France | 32^nd Euro Congress on Cancer Science & Therapy, March 07-08, 2019 Barcelona, Spain | 15^th Global Biomarkers Summit, March 20-21, 2019 Paris, France | 33^rd Global Experts Meeting on Cancer Science & Therapy, April 29-30, 2019 Seoul, South Korea | 3^rd Global Summit on Oncology & Cancer, May 6-7, 2019 Tokyo, Japan | 16^th Asia Pacific Oncologists Annual Meeting, May 13-14, 2019 Singapore | 17^th International Conference on Cancer Research and Therapy, February 27-28, 2019 Seoul, South Korea | 34^th Euro-Global Summit on Cancer Therapy & Radiation Oncology, July 25-27, 2019 London, UK | 4^th World Conference on Breast and Cervical Cancer, October 14-15, 2019 Helsinki, Finland | 31^st Experts Meet On Cancer Therapy, September 13-14, 2019 Singapore | 5^th International Congress on Epigenetics & Chromatin, August 22-23, 2019 Vienna, Austria | 6^th World Congress on Epigenetics and Chromosome, November 22-23, 2019 Dubai, UAE

Asian Societies

European Societies

USA Societies

Track 3: Cancer Diagnostics and Staging

Cancer is suspected in a view of a person’s symptoms, screening tests. Affirmation that Cancer is present requires diagnostic tests which are followed by staging. Staging is way of analysing the tumor, its size, location and the treatment depending on the Cancer stage. It helps to determine the Prognosis of the patient i.e., treatment prediction, disease outcome and patients recovery chances.

4^th World Conference on Breast and Cervical Cancer, October 14-15, 2019 Helsinki, Finland | 31^st Experts Meet On Cancer Therapy, September 13-14, 2019 Singapore | 5^th International Congress on Epigenetics & Chromatin, August 22-23, 2019 Vienna, Austria | 6^th World Congress on Epigenetics and Chromosome, November 22-23, 2019 Dubai, UAE | 26^th Cancer Genomics Congress: New Era for Cancer Prevention, January 21-22, 2019 Dubai, UAE | 17^th International Conference on Cancer Research and Therapy, February 27-28, 2019 Seoul, South Korea | 24^th Annual meet on Surgical Oncology, March 4-5, 2019 Paris, France | 32^nd Euro Congress on Cancer Science & Therapy, March 07-08, 2019 Barcelona, Spain | 15^th Global Biomarkers Summit, March 20-21, 2019 Paris, France | 33^rd Global Experts Meeting on Cancer Science & Therapy, April 29-30, 2019 Seoul, South Korea | 3^rd Global Summit on Oncology & Cancer, May 6-7, 2019 Tokyo, Japan | 16^th Asia Pacific Oncologists Annual Meeting, May 13-14, 2019 Singapore | 17^th International Conference on Cancer Research and Therapy, February 27-28, 2019 Seoul, South Korea | 34^th Euro-Global Summit on Cancer Therapy & Radiation Oncology, July 25-27, 2019 London, UK

Asian Societies

European Societies

USA Societies

Track 4: Cancer Evolution and Research

Throughout history, countless causes of cancer have been proposed including: angering the gods, fermenting or acidic lymph, chronic irritation, trauma, and infection. From the Humoral theory in the middle ages to the discovery of DNA structure in the mid-20^th century, science has found many types and the causes of cancer. These theories stood unchallenged until when Galileo and Newton began to use the scientific method, which laid the foundations for the modern scientific study of disease.

Those theories and beliefs have evolved when you fast forward time nearly 200 years to 2012. And the World Health Organization’s International Agency for Research on Cancer (IARC) identified more than 100 chemical, physical, and biological carcinogens (agents that cause cancer by damaging DNA or disrupting cell metabolism).

To identify causes and develop strategies for prevention, diagnosis, treatment, and cure for cancer, the scientific community is indulged in research work all over the world. May it is research centers, institutes, companies, and hospitals, all contributions account a step by step progress against cancer.

Ranging from molecular bioscience to the clinical trials, Cancer research evaluates and compares applications of various Cancer treatments. Surgery, radiation therapy, chemotherapy, hormone therapy, immunotherapy and combined treatment modalities such as chemo-radiotherapy being such applications. The mid-1990s marks the shifting of clinical cancer research to therapies derived from biotechnology research, such as cancer immunotherapy and gene therapy.

Asian Societies

European Societies

USA Societies

Track 5: Cancer APIs and Clinical Trials

The Active Pharmaceutical Ingredient (API) is the part of any drug that is biologically active. All drugs are made up of two core components: the API, which is the central ingredient, and the excipients (chemically inactive substances such as lactose or mineral oil) that help deliver the medication to our system. Abiraterone acetate, Anastrozole, Bendamustine are few names among the anti-cancer API products.

The end step in a long process that begins in a research lab is Clinical Trials. After many years of research work to understand its effects on cancer cells in the lab and in animals, a new treatment is used for people in clinical trials.

Through clinical trials, doctors determine whether the new treatments are safe and effective and work better than current treatments. It helps in finding new ways to prevent and detect cancer and also to improve the quality of life for people during and after treatment.

Asian Societies

European Societies

USA Societies

Track 6: Cancer Treatment, Therapy and Nursing

Early treatments focused on improving surgical techniques for removing tumors. It was the 1900s when Radiation therapy and Chemotherapeutics came into the picture and were refined throughout the 20th century.

Emerging topics in cancer treatment research include:

Anti-cancer vaccines
Newer forms of chemotherapy
Gene therapy
Photodynamic therapy
Radiation therapy
Reoviridae (Reolysin drug therapy)
Targeted therapy
Natural killer cells can induce immunological memory

Research is being developed to modify their action against cancer.

Oncology nursing care is also an important aspect in the treatment of cancer which meets the various needs of oncology patients during the time of their disease including appropriate screenings, preventive practices, symptom management, care to retain as much normal functioning as possible, and supportive measures upon the end of life. These nurses need advanced certifications and clinical experiences in oncology further than the typical bachelorette nursing program provides.

Oncology nurses can work inpatient settings such as hospitals, outpatient settings, in hospice services, or in physician offices in a variety of specialities such as radiation, surgery, pediatric, or gynecologic. Oncology nurses have advanced knowledge of assessing the client’s status which will help the multi-disciplinary medical team to develop a treatment plan.

Asian Societies

European Societies

USA Societies

Track 7: Cancer Case Studies

A case study is a research method involving an up-close, in-depth, and detailed examination of a concerned subject/topic (or the case), as well as its related contextual conditions. Case studies can be produced by following a formal research method which may be by an individual, organization, event, or action, existing in a specific time and place. Here we are inviting case studies based on cancer and followings are the focused streams. You can present your studies on any other type of cancer as well. The presenter in this category will receive a 30% discount on registration.

Childhood Cancer
Breast Cancer
Lung Cancer

Asian Societies

European Societies

USA Societies

Track 8: Cancer Epigenetics

Epigenetics refers to the heritable change in gene expression that does not involve changes to the underlying DNA sequence. DNA methylation, histone modifications and non-coding RNAs (ncRNA) play fundamental roles in epigenetic regulation.

The study of epigenetic modifications of the Cancer cell genome that does not involve a change in the nucleotide sequence is called Cancer Epigenetics. Risk expectation, Prediction and Cancer prevention, growth counteractive actions are also promising and encouraging areas of Epigenetics. A high adequacy of demethylating agents was accounted for essentially in haematological malignancies in view of new conventions with the low dose and long exposure, and their utilization is presently being striven for strong tumors.

During the cell transformation to a cancerous cell, Epigenetic modifications are also important like genetic mutations. Their manipulation brings a promising approach for prevention, detection, and therapy of Cancer.

Asian Societies

European Societies

USA Societies

Track 9: Clinical Epigenetics

The application of molecular biology techniques in detection of alterations in DNA methylation or histone modification to diagnose or study disorders characterized by heritable defects in the expression of a gene or genome is referred to as Clinical epigenetics.

Asian Societies

European Societies

USA Societies

Track 10: Epigenetics and Chromatin

Chromatin is a complex of DNA, RNA, and protein which packages very long DNA molecules into a more compact, denser shape, preventing the strands from becoming tangled, preventing DNA damage, and regulating gene expression and DNA replication. Epigenetic modification of the structural proteins in chromatin via methylation and acetylation also alters local chromatin structure and thus gene expression. The structure of chromatin networks is currently poorly understood and hence is an active area of research in molecular biology.

Asian Societies

European Societies

USA Societies

Track 11: Epigenetic Therapy

Epigenetic therapy is the use of drugs or other epigenome-influencing techniques to treat medical conditions such as cancer, heart disease, diabetes, and mental illnesses. Epigenetic therapies are among the most active areas of preclinical and clinical cancer research evidence to their potential of specifically targeting chromatin-mediated disease mechanisms. It is expected that these therapies will have fewer side effects than conventional cytotoxic chemotherapies. Several classes of drugs have emerged, and several are on-going development.

The DNMT inhibitors 5-azacytidine and 5-aza-20-deoxycytidine have both been approved by the FDA for the treatment of various forms of cancer. These drugs have been evident to reactivate the cellular antitumor systems which are repressed by cancer, hence enabling the body to weaken the tumor.

Asian Societies

European Societies

USA Societies

Track 12: Epigenetic Biomarker

A cancer biomarker is a biological marker which indicates the presence of cancer in the body. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers are used for diagnosis, prognosis, and epidemiology of cancer.

Because they are expressed against a person's genetic background and environmental exposure, and epigenetic events occur early in cancer development, Epigenetic biomarkers are more advantageous over other types of biomarkers.

Epigenetic biomarkers potentially have numerous clinical applications in cancer intervention and treatment and significant implications for public health.

Types of epigenetic biomarkers:

DNA methylation, circulating or noncirculating
MicroRNA and other noncoding RNA
Protein markers

For e.g., DNA methylation is one of the major epigenetic mechanisms and it is a genetic feature better reflecting disease development and, consequently, has the potential to become a more conclusive biomarker for detection and diagnosis of different diseases.

Asian Societies

European Societies

USA Societies

Track 13: Chromatin Remodeling and Cancer

Chromatin remodeling is the rearrangement of chromatin architecture to allow access of condensed genomic DNA to the regulatory transcription machinery proteins, allowing transcription factors or other DNA binding proteins to access DNA and control gene expression. Targeting chromatin remodeling pathways is evolving as a major therapeutic strategy in the treatment of several cancers.

Chromatin remodeling provides fine-tuning at crucial cell growth and division steps, like cell-cycle progression, DNA repair and chromosome segregation, and hence exerts tumor-suppressor function.

Asian Societies

European Societies

USA Societies

Track 14: Histone Modifications and Cancer

Cancer is considered to have a clonal origin but cancer tissues are comprised of a heterogeneous group of cells with different functional potential. Alterations in the modifications of histones have been linked to deregulated expression of many genes with important roles in cancer development and progression. Histones are the class of proteins bundled within a DNA that promote the effects of DNA methylation on gene expression indirectly. In contrast to the stable effects of DNA methylation, histone modifications have greater plasticity in determining the expression or silencing of specific genes in response to stimuli.

Asian Societies

European Societies

USA Societies

Track 15: Artificial Intelligence and Cancer

When cancer is detected early, it is more likely that the treatment will be successful. But more often, cancers are diagnosed at a late stage when they are much harder to treat. The biggest challenge in cancer treatment is the ever-changing nature of tumours with cancers often evolving to a drug-resistant form. If doctors can predict the evolution of a tumour, they could intervene earlier to stop cancer in its tracks before it gets the chance to evolve or develop resistance, thereby increasing the patient’s chances of survival.

Artificial Intelligence has been used by scientists to predict how cancers will progress and evolve, so that doctors can design the most effective treatment for each patient. For e.g., a new technique was developed called REVOLVER (Repeated evolution of cancer), which picks out patterns in DNA mutation within cancers and uses the information to forecast future genetic changes.

Asian Societies

European Societies

USA Societies

Market Analysis

In the last few years, the market for Cancer profiling in the Asia-Pacific region has seen huge development as a result of the increasing incidence of Cancer, high demand for better healthcare services.

High prevalence of Cancer; expanding R&D subsidizing; expanding power of research exercises; expanding application for non-oncology illnesses; and developing organization between scholarly, biotechnology and pharmaceutical organizations are driving components of the Cancer Genomics and epigenetics market

Cancer Profiling Market is divided into Application, Diagnosis, Technique, Technology etc.

By Application, it consists of :

Diagnostic
Personalized Medicine
Research

By Technique, it consists of :

Genomics
Proteomics
Metabolomics
Epigenetics

By Technology, it consists of :

Next-generation Sequencing
qPCR
In-situ Hybridization
Microarray

It is estimated that the worldwide Cancer Profiling business sector is ready to achieve USD 61.87 Billion by 2021 from USD 25.82 Billion in 2016 according to the "Cancer Profiling Market".The following graph depicts the data pictorially.

Central point powering market development is increasing the number of malignancy cases over the globe.

Components, for example, the expanding interest in personalized medicine and point-of-care diagnostic tests in Cancer profiling are required to offer an extensive variety of development open doors for players in the tumour profiling market. The personalized medicine segment to represent the biggest share of the worldwide cancer profiling application showcase in 2016.

Across the board, continuous research in the part of Epigenetics in diseases and disorders in humans is fuelling the worldwide epigenetics drugs, diagnostic technologies, and indicative advances.

In light of research territories, the market for Epigenetics is fragmented into developmental biology, drug discovery, oncology, and other research areas. Other research areas include genome-wide regulatory mechanisms and research related to several metabolic and genetic diseases.

In light of geology, the market of Epigenetics is divided into North America, Europe, Asia, and the Rest of the World. North America is further sub-segmented into the U.S. Furthermore, Canada. In Asia, the degree for this present market's development is extending quickly. Asia represents a large portion of all cancer cases analyzed around the world. This makes helpful conditions for the development of the Epigenetic medications and diagnostics advertise in Asian nations, particularly China, Japan, Australia, and South Korea, with Japan in the prevailing position.

As per the National Cancer Institute, malignancy is among the main sources of death around the world, for which according to a recent review, epigenetic inhibitors comprise of the attributes and capacities which have the potential in cancer prevention and control. This element has given an impulse to the examination directed on epigenetics in the oncology business

In the estimated period between 2015 to 2020, the Epigenetics market is relied upon to stay as the number of new participants in this market will continue ascending with the consistent appearance of new innovations combined with upgraded highlights.

The Asia Pacific market is estimated to witness lucrative growth over the forecast period owing to, the presence of a large prevalence of target diseases and high unmet medical needs. Technology progressions in the field of epigenetics particularly relating to the location of methylation markers identified with growth advancement is relied upon to enhance utilization rates.

Epigenetic reagents were the biggest market esteemed at over USD 1.2 billion in 2014 attributable to the expanding measure of R&D ventures and high utilization rates. Kits are relied upon to increase quick development sought after because of the expanding need for rapid and accurate detection techniques.

DNA methylation was the biggest innovation portion representing more than 47.0% income in 2014. Oncology was the biggest application showcase, with income esteemed at over USD 2.75 billion. The non-oncology segment is anticipated to register the fastest development of over 20.0% during the forecast period. The segment is dominated by metabolic diseases owing to, the growing base of the population suffering from diabetes and organ failure and increasing prevalence of sedentary lifestyle.

Owing to the increasing economic burden of diseases such as cancer and diabetes, governments across the world are advocating the adoption of early disease detection and diagnosis. Early cancer detection, especially, is being encouraged through screening kits. This is helping the development of the worldwide epigenetics drugs and indicative advancements advertise, states the report.

The overall business division of Epigenetics is divided in light of items, research domains, and topography. By item, the business area consolidates catalysts, instruments and consumables, packs and reagents. Instruments and consumables are further sub-segmented into mass spectrometers, cutting-edge sequencers, qPCRs, sonicators and different epigenetics instruments and consumables. Other research zones consolidate expansive managerial instruments and research related to metabolic and inherited diseases.

Epigenetics Product Outlook (Revenue, USD Million, 2015 – 2022)

Reagents
Kits
Instruments
Enzymes
Services

Epigenetics Technology Outlook (Revenue, USD Million, 2015 – 2022)

DNA Methylation
Histone Methylation
Histone Acetylation
Large noncoding RNA
MicroRNA Modification
Chromatin structures

Epigenetics Application Outlook (Revenue, USD Million, 2015 – 2022)

Oncology
Solid Tumors
Liquid Tumors
Non-Oncology
Inflammatory Diseases
Metabolic Diseases
Infectious Diseases
Cardiovascular Diseases

Epigenetics Market Regional Outlook (Revenue, USD Million, 2015 – 2022)

North America
USA
Canada
Europe
UK
Germany
Asia Pacific
Japan
China
India
Latin America
Brazil
Mexico
Middle East and Africa (MEA)
South Africa

Past Conference Report

Epigenetics and Cancer 2017

Epigenetics and Biomarkers 2017: Past Conference Report

The success of the Epigenetics and Biomarkers 2017 conference has given us the prospect to bring the gathering one more time. Conference Series LLC Ltd hosted the “International Conference on Cancer Epigenetics and Biomarkers” during October 26-28, 2017 at Hyatt Regency Osaka, Japan.

The conference was focused on learning about Oncologists with the theme “From Novel therapies to Revolutionary Strategies, Diagnosis and Treatment”. The conference mainly directs towards addressing main issues like Prevention, Diagnosis, and Treatment diseases of the Organ-related Cancers and its innovative techniques. Epigenetics and Biomarkers 2017 is one of the most appreciated Cancer Conferences organized by Conference Series LLC Ltd. This Oncologists Meeting was discussed on methods and strategies related to management, quality improvement of Cancer as well as to explore the new ideas and concepts on a global scale and the topics include lung cancer, breast cancer, bone cancer, blood cancer, cervical cancer, colon-rectum cancer, prostate cancer, thyroid cancer.

The conference was embarked with an opening ceremony followed by Keynote sessions and followed by a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were:

Suraiya Rasheed, University of Southern California, United States

Biomarkers of a stem cell melanoma

Jenny Wang, University of New South Wales, Australia

Epigenetic and metabolic regulation of leukemia stem cells

Manal H. Al Khanbashi, Higher College of Technology, Oman

Insights of breast cancer epigenetics: An intersection between the endogenous and exogenous systems

Pedro Sanchez Rovira, Xanit International Hospital, Spain

A metabolomics approach for therapy response in breast cancer

David A Ligon, Oncology Fox, United States

Leading the global collaborative effort in epigenetics through a next generation search engine and portal for the oncology community

Atsushi Kaneda, Chiba University, Japan

Induction of epigenetic alterations in gastric epithelium and their contribution to gastric tumorigenesis

Glenn Deng, Stanford University School of Medicine, United States

Single-cell molecular analysis reveals a possibility of epithelial to circulating tumor cell transition when a tumor cell enters into the bloodstream

Ladan Teimoori-Toolabi, Molecular Medicine Department, Pasteur Institute of Iran, Iran

Studying methylation status of p16, p14, MLH1, APC and UNC5C in the plasma as diagnostic biomarkers of colorectal cancer

Sang Hyun Lee, Duke-NUS Medical School, Singapore

Dual blockade of the lipid kinase and mitotic pathways leads to Ras activated cancer-selective lethality

Jose Perez del Palacio, MEDINA Foundation, Spain

Predictive biomarker discovery of treatment response in lung cancer: A metabolomic approach

Safana Salim Al Saidi, Ministry Of Health, Muscat

Validity of prostate health index and percentage of [-2]pro-prostate-specific antigen as novel biomarkers in the diagnosis of prostate cancer first reported Omani tertiary hospitals experience

In-Hye Jung, University of Ulsan College of Medicine, Seoul, South Korea

EGF induces paradoxical growth arresting via the up-regulation of PTEN by activating Ref-1/Egr-1 in human NSCLC cells

We express our heartfelt appreciation to Organizing Committee Members, dexterous of the field, various outside experts, company representatives and is obliged to other eminent personalities who interlaced with us and supported the conference in every aspect, without which the conference would not have been possible.

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Epigenetics and Biomarkers 2017, Conferencesereies LLC Ltd would like to announce the commencement of the “3^rd International Conference on Cancer Genetics and Epigenetics” to be held during October 23-24, 2019 in Tokyo, Japan. We welcome all the eminent researchers, students and delegate participants to take part in this upcoming conference to witness invaluable scientific discussions and contribute to the future innovations in the field of Oncology and Cancer Research.

More details: https://epigeneticsconference.conferenceseries.com/

Let us meet again @ Epigenetics and Cancer 2019

Past Reports Gallery

To Collaborate Scientific Professionals around the World

Conference Date October 23-24, 2019

For Sponsors & Exhibitors

sponsor@conferenceseries.com

Speaker Opportunity

Poster Opportunity E-Poster Opportunity

Useful Links

Past Conference Report

Epigenetics and Cancer 2018 Conference

Supported By

Journal of Cancer Science & Therapy Journal of Integrative Oncology Journal of Carcinogenesis & Mutagenesis

All accepted abstracts will be published in respective Conference Series International Journals.

Abstracts will be provided with Digital Object Identifier by

Epigenetics and Cancer Medicine

October 23-24, 2019 Tokyo, Japan

The curious science of Cancer Epigenetics: A spotlight on research & patient connection

Cancer Conference | Epigenetics Conference | Epigenetics & Cancer 2019 | Oncology Conference | Asia | USA | Europe | Middle East | 2019 | Conference Series

Conference Series Conferences gaining more Readers and Visitors

Renowned Speakers

Suraiya Rasheed

Jenny Wang

Manal H Al Khanbashi

Pedro Sanchez Rovira

David A Ligon

Atsushi Kaneda

Ladan Teimoori-Toolabi

Sang Hyun Lee

Recommended Global Oncology & Cancer Webinars & Conferences

Europe & UK

Asia Pacific & Middle East

Canada

epigenetics conference 2019

About Conference

Suggestions

Session Topics

Market Analysis

Past Conference Report

To Collaborate Scientific Professionals around the World

Useful Links

Past Conference Report

Supported By